EGFR and non-small cell lung carcinoma: For these reasons, the 5-years survival rate for the disease is still below 21% (Lu et al., 2019), and new cost-effective therapeutic strategies are urgently needed to overcome poor chemotherapy response in EGFR WT NSCLC patients.